B. Metzler seel. Sohn & Co. AG Invests $14.24 Million in Boston Scientific Corporation $BSX

Key Points

• B. Metzler seel. Sohn & Co. AG acquired 333,583 Boston Scientific shares in the second quarter, valued at approximately $14.24 million. Institutional investors collectively own 89.07% of the company.
• Boston Scientific exceeded quarterly expectations, reporting $0.86 in earnings per share versus the $0.83 consensus estimate and $5.44 billion in revenue, up 7.5% year over year.
• The company authorized a $5 billion share-repurchase program, while analysts maintain a “Moderate Buy” consensus rating with an average price target of $71.62.

B. Metzler seel. Sohn & Co. AG bought a new position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 333,583 shares of the medical equipment provider's stock, valued at approximately $14,237,000.

A number of other large investors have also recently bought and sold shares of the company. Kelleher Financial Advisors purchased a new stake in shares of Boston Scientific in the 2nd quarter valued at $25,000. FWL Investment Management LLC purchased a new position in shares of Boston Scientific during the second quarter worth $26,000. Swiss RE Ltd. acquired a new position in Boston Scientific during the fourth quarter valued at $26,000. Garton & Associates Financial Advisors LLC purchased a new stake in Boston Scientific in the fourth quarter valued at $26,000. Finally, Clal Insurance Enterprises Holdings Ltd acquired a new stake in Boston Scientific during the 1st quarter worth about $28,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Performance

NYSE BSX opened at $49.47 on Friday. The stock has a market capitalization of $71.69 billion, a price-to-earnings ratio of 20.03, a PEG ratio of 1.13 and a beta of 0.56. The stock has a 50-day moving average of $46.26 and a 200 day moving average of $57.91. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.Boston Scientific's quarterly revenue was up 7.5% compared to the same quarter last year. During the same period last year, the company earned $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Sell-side analysts anticipate that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific declared that its board has authorized a stock repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

BSX has been the topic of several analyst reports. Wells Fargo & Company dropped their target price on Boston Scientific from $55.00 to $50.00 and set an "equal weight" rating on the stock in a report on Thursday, July 30th. The Goldman Sachs Group set a $71.00 price target on Boston Scientific in a report on Thursday, May 28th. Truist Financial dropped their price objective on shares of Boston Scientific from $62.00 to $57.00 and set a "buy" rating on the stock in a research note on Thursday, July 30th. Wall Street Zen lowered shares of Boston Scientific from a "buy" rating to a "hold" rating in a report on Sunday, August 2nd. Finally, BTIG Research decreased their target price on shares of Boston Scientific from $65.00 to $60.00 and set a "buy" rating for the company in a research note on Wednesday, July 29th. Twenty-four analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $71.62.

Insider Activity

In related news, Director David C. Habiger purchased 2,100 shares of Boston Scientific stock in a transaction that occurred on Wednesday, August 5th. The stock was purchased at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the transaction, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Edward J. Ludwig purchased 5,000 shares of the firm's stock in a transaction that occurred on Friday, July 31st. The stock was bought at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the purchase, the director directly owned 30,359 shares in the company, valued at $1,380,727.32. This represents a 19.72% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 194,522 shares of company stock worth $9,385,210 over the last 90 days. 0.34% of the stock is currently owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.